Abstracts tagged "survivin"

Abstract Number: 1765 • 2019 ACR/ARP Annual Meeting
Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis
Malin Erlandsson ¹, Karin Andersson ¹, Nisha Nair ², Anastasius Damdimopoulos ³, Sofia Silfverswärd ¹, Rille Pullerits ¹, Anne Barton ² and Maria Bokarewa¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ³Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden
Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage,…
Abstract Number: 2001 • 2019 ACR/ARP Annual Meeting
Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin
Karin Andersson ¹, Malin Erlandsson ¹, Anastasius Damdimopoulos ², Robin Bremer ¹, Maja Jensen ³, Maria-José Garcia-Bonete ³, Gergely Katona ³ and Maria Bokarewa¹, ¹Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, ²Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden, ³Department of Chemistry and Molecular Biology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: The oncoprotein survivin coded by the BIRC5 gene was described as an important marker in rheumatoid arthritis (RA). Survivin participates in cell division being…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].